The hemostats market size has grown strongly in recent years. It will grow from $3.56 billion in 2025 to $3.8 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing volume of surgical procedures, expansion of hospital surgical infrastructure, advancements in biomaterial technologies, growing demand for effective blood loss management, wider adoption of minimally invasive surgeries.
The hemostats market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing focus on patient safety outcomes, rising demand for faster surgical recovery, expansion of advanced trauma care facilities, growing innovation in bioactive hemostatic materials, increasing adoption of specialty surgical products. Major trends in the forecast period include increasing use of advanced combination hemostats, rising adoption of ready-to-use hemostatic agents, growing demand for rapid bleeding control solutions, expansion of biocompatible and absorbable products, enhanced focus on surgical efficiency and safety.
An increase in surgical procedures is expected to accelerate the growth of the hemostat market going forward. Surgical procedures include all forms of invasive medical interventions used to diagnose or treat pathological conditions. Hemostats play a critical role during surgical procedures, as they are used to control bleeding and minimize blood loss during operations. For instance, in June 2024, according to the American Society of Plastic Surgeons, a United States-based non-profit organization, minimally invasive procedures increased by 7% in 2023, surpassing the growth rate of surgical procedures by 2%. Hand surgeries, including procedures for carpal tunnel syndrome, arthritis, and trigger finger, accounted for 207,887 cases, representing a 2% increase compared to 2022. Therefore, the rising number of surgical procedures is driving the growth of the hemostat market.
The growing prevalence of trauma cases is expected to propel the growth of the haemostat market going forward. Trauma cases involve medical emergencies caused by external physical forces that require immediate assessment and treatment. The increase in trauma incidents is largely attributed to the rise in road accidents, as higher traffic density and unsafe driving practices result in more severe injuries requiring urgent medical intervention. Hemostats are crucial in trauma care, as they enable rapid bleeding control at injury sites, helping healthcare professionals stabilize patients more efficiently and improve survival rates. For example, in October 2024, according to the Alaska Department of Health, a United States-based government agency, approximately 3,373 individuals in Alaska sustained traumatic brain injuries in 2023, including both fatal cases and non-fatal injuries treated and released from hospitals or emergency departments. Therefore, the increasing incidence of trauma cases is contributing to the growth of the haemostat market.
Major companies are increasingly engaging in partnerships and collaborations with start-ups and mid-sized firms to strengthen their presence in the hemostat space and expand their product and service offerings. These strategic alliances enable companies to enhance their product portfolios while also extending their geographic reach. For instance, in May 2023, Olympus, a Japan-based manufacturer of optics and reprography products, expanded its partnership with Endoclot, a United States-based medical device company, to introduce hemostatic agents. The inclusion of these solutions in Olympus’ portfolio enables the company to support safer gastrointestinal procedures and contribute to improved patient outcomes, thereby helping to raise overall standards of care.
Major companies operating in the hemostats market are B. Braun Melsungen AG, Baxter International Inc., Integra LifeSciences Corporation, Becton Dickinson and Company, Teleflex Incorporated, Medtronic PLC, Hemostasis LLC, Stryker Corporation, Advanced Medical Solutions Group PLC, Samyang Holdings Corporation, Gelita Medical GmbH, CryoLife Inc., CuraMedical B.V., Meril Life Sciences Pvt. Ltd., Beijing Datsing Bio-Tech Co. Ltd., Zhonghui Shengxi (Beijing) Medical Technology Co. Ltd., Biotemed Inc., Biom'up SA, Shandong Foryou Medical Devices Co. Ltd., Z-Medica LLC, Anika Therapeutics Inc.
North America was the largest region in the hemostats market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemostats market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemostats market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hemostats market by increasing costs of imported biomaterials, collagen, gelatin, thrombin derivatives, and advanced packaging materials. Surgical centers in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces cost pressures in export-oriented manufacturing. These tariffs are increasing product prices and affecting procurement budgets. However, they are also encouraging local sourcing of biomaterials, regional manufacturing expansion, and innovation in cost-effective hemostatic solutions.
The hemostats market research report is one of a series of new reports that provides hemostats market statistics, including hemostats industry global market size, regional shares, competitors with a hemostats market share, detailed hemostats market segments, market trends and opportunities, and any further data you may need to thrive in the hemostats industry. This hemostats market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A hemostat is a surgical tool employed in various surgical procedures to control or compress bleeding vessels, facilitating the treatment of wounds and aiding in visualizing deeper regions during surgeries.
There are several types of hemostats, including thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. Thrombin-based hemostats are used to control and reduce blood loss during surgical procedures, either in conjunction with or as an alternative to traditional surgical techniques. Thrombin is an enzyme that breaks down fibrinogen into fibrin, promoting blood clotting. Examples of active hemostats include topical (bovine) thrombin (Thrombin-JMI), topical (human) thrombin (Evithrom), and topical (recombinant) thrombin (Recothrom). They are available in various forms, such as active hemostats, passive hemostats, combination hemostats, and others. Formulations include matrix and gel hemostats, sheet and pad hemostats, sponge hemostats, and powder hemostats. These hemostats find applications in orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, gynecological surgery, and other medical procedures.
The hemostat market consists of sales of cellulose based and thrombin-based hemostats. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hemostats market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing focus on patient safety outcomes, rising demand for faster surgical recovery, expansion of advanced trauma care facilities, growing innovation in bioactive hemostatic materials, increasing adoption of specialty surgical products. Major trends in the forecast period include increasing use of advanced combination hemostats, rising adoption of ready-to-use hemostatic agents, growing demand for rapid bleeding control solutions, expansion of biocompatible and absorbable products, enhanced focus on surgical efficiency and safety.
An increase in surgical procedures is expected to accelerate the growth of the hemostat market going forward. Surgical procedures include all forms of invasive medical interventions used to diagnose or treat pathological conditions. Hemostats play a critical role during surgical procedures, as they are used to control bleeding and minimize blood loss during operations. For instance, in June 2024, according to the American Society of Plastic Surgeons, a United States-based non-profit organization, minimally invasive procedures increased by 7% in 2023, surpassing the growth rate of surgical procedures by 2%. Hand surgeries, including procedures for carpal tunnel syndrome, arthritis, and trigger finger, accounted for 207,887 cases, representing a 2% increase compared to 2022. Therefore, the rising number of surgical procedures is driving the growth of the hemostat market.
The growing prevalence of trauma cases is expected to propel the growth of the haemostat market going forward. Trauma cases involve medical emergencies caused by external physical forces that require immediate assessment and treatment. The increase in trauma incidents is largely attributed to the rise in road accidents, as higher traffic density and unsafe driving practices result in more severe injuries requiring urgent medical intervention. Hemostats are crucial in trauma care, as they enable rapid bleeding control at injury sites, helping healthcare professionals stabilize patients more efficiently and improve survival rates. For example, in October 2024, according to the Alaska Department of Health, a United States-based government agency, approximately 3,373 individuals in Alaska sustained traumatic brain injuries in 2023, including both fatal cases and non-fatal injuries treated and released from hospitals or emergency departments. Therefore, the increasing incidence of trauma cases is contributing to the growth of the haemostat market.
Major companies are increasingly engaging in partnerships and collaborations with start-ups and mid-sized firms to strengthen their presence in the hemostat space and expand their product and service offerings. These strategic alliances enable companies to enhance their product portfolios while also extending their geographic reach. For instance, in May 2023, Olympus, a Japan-based manufacturer of optics and reprography products, expanded its partnership with Endoclot, a United States-based medical device company, to introduce hemostatic agents. The inclusion of these solutions in Olympus’ portfolio enables the company to support safer gastrointestinal procedures and contribute to improved patient outcomes, thereby helping to raise overall standards of care.
Major companies operating in the hemostats market are B. Braun Melsungen AG, Baxter International Inc., Integra LifeSciences Corporation, Becton Dickinson and Company, Teleflex Incorporated, Medtronic PLC, Hemostasis LLC, Stryker Corporation, Advanced Medical Solutions Group PLC, Samyang Holdings Corporation, Gelita Medical GmbH, CryoLife Inc., CuraMedical B.V., Meril Life Sciences Pvt. Ltd., Beijing Datsing Bio-Tech Co. Ltd., Zhonghui Shengxi (Beijing) Medical Technology Co. Ltd., Biotemed Inc., Biom'up SA, Shandong Foryou Medical Devices Co. Ltd., Z-Medica LLC, Anika Therapeutics Inc.
North America was the largest region in the hemostats market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemostats market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemostats market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hemostats market by increasing costs of imported biomaterials, collagen, gelatin, thrombin derivatives, and advanced packaging materials. Surgical centers in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces cost pressures in export-oriented manufacturing. These tariffs are increasing product prices and affecting procurement budgets. However, they are also encouraging local sourcing of biomaterials, regional manufacturing expansion, and innovation in cost-effective hemostatic solutions.
The hemostats market research report is one of a series of new reports that provides hemostats market statistics, including hemostats industry global market size, regional shares, competitors with a hemostats market share, detailed hemostats market segments, market trends and opportunities, and any further data you may need to thrive in the hemostats industry. This hemostats market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A hemostat is a surgical tool employed in various surgical procedures to control or compress bleeding vessels, facilitating the treatment of wounds and aiding in visualizing deeper regions during surgeries.
There are several types of hemostats, including thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. Thrombin-based hemostats are used to control and reduce blood loss during surgical procedures, either in conjunction with or as an alternative to traditional surgical techniques. Thrombin is an enzyme that breaks down fibrinogen into fibrin, promoting blood clotting. Examples of active hemostats include topical (bovine) thrombin (Thrombin-JMI), topical (human) thrombin (Evithrom), and topical (recombinant) thrombin (Recothrom). They are available in various forms, such as active hemostats, passive hemostats, combination hemostats, and others. Formulations include matrix and gel hemostats, sheet and pad hemostats, sponge hemostats, and powder hemostats. These hemostats find applications in orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, gynecological surgery, and other medical procedures.
The hemostat market consists of sales of cellulose based and thrombin-based hemostats. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hemostats Market Characteristics
3. Hemostats Market Supply Chain Analysis
4. Global Hemostats Market Trends and Strategies
5. Hemostats Market Analysis of End Use Industries
7. Global Hemostats Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hemostats Total Addressable Market (TAM) Analysis for the Market
9. Hemostats Market Segmentation
10. Hemostats Market Regional and Country Analysis
11. Asia-Pacific Hemostats Market
12. China Hemostats Market
13. India Hemostats Market
14. Japan Hemostats Market
15. Australia Hemostats Market
16. Indonesia Hemostats Market
17. South Korea Hemostats Market
18. Taiwan Hemostats Market
19. South East Asia Hemostats Market
20. Western Europe Hemostats Market
21. UK Hemostats Market
22. Germany Hemostats Market
23. France Hemostats Market
24. Italy Hemostats Market
25. Spain Hemostats Market
26. Eastern Europe Hemostats Market
27. Russia Hemostats Market
28. North America Hemostats Market
29. USA Hemostats Market
30. Canada Hemostats Market
31. South America Hemostats Market
32. Brazil Hemostats Market
33. Middle East Hemostats Market
34. Africa Hemostats Market
36. Hemostats Market Competitive Landscape and Company Profiles
37. Hemostats Market Other Major and Innovative Companies
40. Hemostats Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hemostats Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hemostats market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hemostats? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemostats market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Composition: Thrombin-Based Hemostats; Oxidized Regenerated Cellulose-Based Hemostats; Combination Hemostats; Gelatin-Based Hemostats; Collagen-Based Hemostats2) By Product: Active Hemostats; Passive Hemostats; Combination Hemostats; Other Products
3) By Formulation: Matrix And Gel Hemostats; Sheet And Pad Hemostats; Sponge Hemostats; Powder Hemostats
4) By Application: Orthopedic Surgery; General Surgery; Neurological Surgery; Cardiovascular Surgery; Reconstructive Surgery; Gynecological Surgery; Other Applications
Subsegments:
1) By Thrombin-Based Hemostats: Topical Thrombin; Lyophilized Thrombin2) By Oxidized Regenerated Cellulose-Based Hemostats: Pads; Granules
3) By Combination Hemostats: Thrombin And Gelatin Combinations; Thrombin And Collagen Combinations
4) By Gelatin-Based Hemostats: Gelfoam; Gelatin Sponge
5) By Collagen-Based Hemostats: Collagen Sheets; Collagen Powder
Companies Mentioned: B. Braun Melsungen AG; Baxter International Inc.; Integra LifeSciences Corporation; Becton Dickinson and Company; Teleflex Incorporated; Medtronic PLC; Hemostasis LLC; Stryker Corporation; Advanced Medical Solutions Group PLC; Samyang Holdings Corporation; Gelita Medical GmbH; CryoLife Inc.; CuraMedical B.V.; Meril Life Sciences Pvt. Ltd.; Beijing Datsing Bio-Tech Co. Ltd.; Zhonghui Shengxi (Beijing) Medical Technology Co. Ltd.; Biotemed Inc.; Biom'up SA; Shandong Foryou Medical Devices Co. Ltd.; Z-Medica LLC; Anika Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hemostats market report include:- B. Braun Melsungen AG
- Baxter International Inc.
- Integra LifeSciences Corporation
- Becton Dickinson and Company
- Teleflex Incorporated
- Medtronic PLC
- Hemostasis LLC
- Stryker Corporation
- Advanced Medical Solutions Group PLC
- Samyang Holdings Corporation
- Gelita Medical GmbH
- CryoLife Inc.
- CuraMedical B.V.
- Meril Life Sciences Pvt. Ltd.
- Beijing Datsing Bio-Tech Co. Ltd.
- Zhonghui Shengxi (Beijing) Medical Technology Co. Ltd.
- Biotemed Inc.
- Biom'up SA
- Shandong Foryou Medical Devices Co. Ltd.
- Z-Medica LLC
- Anika Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.8 Billion |
| Forecasted Market Value ( USD | $ 5.02 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
